Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants Read More
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval Read More
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 Read More
Investor Relations Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up Read More
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates Read More
